Navidea Biopharmaceuticals (NAVB) Drops 7.45% on January 27

Equities Staff |

Navidea Biopharmaceuticals (NAVB) was one of the Russell 2000's biggest losers for Wednesday January 27 as the stock slid 7.45% to $0.87, a loss of $-0.07 per share. Starting at an opening price of $0.92 a share, the stock traded between $0.86 and $0.92 over the course of the trading day. Volume was 389,088 shares over 1,114 trades, against an average daily volume of 690,384 shares and a total float of 155.7 million.

The losses send Navidea Biopharmaceuticals down to a market cap of $135.46 million. In the last year, Navidea Biopharmaceuticals has traded between $2.50 and $0.79, and its 50-day SMA is currently $1.34 and 200-day SMA is $1.65.

Navidea Biopharmaceuticals Inc is a precision medicine company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents.

Navidea Biopharmaceuticals is based out of Dublin, OH and has some 54 employees. Its CEO is Ricardo J. Gonzalez.

For a complete fundamental analysis analysis of Navidea Biopharmaceuticals, check out Equities.com’s Stock Valuation Analysis report for NAVB. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Breathtec BioMedical Inc.

Breathtec Biomedical Inc is a medical diagnostics company. It is engaged in developing & commercializing breath analysis devices for the early detection of infections & life threatening diseases including cancers,…

Private Markets

Cloudera

Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…

Pinterest

Pinterest is a visual discovery and planning tool. Users ("Pinners") use the site and apps to get ideas for their future, such as recipes, places to travel, and products to…